Indeed, epigenetic modifiers, including valproic acid and UNC0642, were represented in our top hits from the chemical screen of compounds that prevented CAF2 from reducing ER-α activity in breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.